甲福明可以改善肠粘膜屏障功能,帮助预防和逆转小鼠结肠直肠癌
Ruiqi Wang1,2, Longke Xie1,2, Ping Jiang3
1Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, China.
Journal of Cancer
|September 19, 2025
概括
梅特福林通过改善肠道屏障功能,减少了小鼠的结肠直肠癌 (CRC) 瘤. 这表明甲福明可以通过恢复结肠中的紧结蛋白来保护CRC.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大肠直肠癌 (CRC) 是一个重大的健康问题.
- 建议在CRC中进行甲胺的预防作用,但需要阐明底层机制.
- 肠道粘膜屏障的完整性对于CRC的发展至关重要.
研究的目的:
- 研究甲福明对结肠直肠癌 (CRC) 发病和进展的影响.
- 在CRC小鼠模型中评估甲福明对肠粘膜屏障的影响.
- 为了确定甲胺对CRC和屏障功能的剂量依赖作用.
主要方法:
- 一个结直肠癌 (CRC) 鼠标模型是使用氧甲和硫酸德克斯建立的.
- BALB/C雌性小鼠被分为对照组,模型组和低,中,高剂量甲胺组.
- 甲胺被用在125,250和500毫克/公斤/天的剂量中,持续14周,并进行瘤分析和紧结蛋白表达 (ZO-1,ocludin) 评估.
主要成果:
- 对照组没有观察到瘤;所有其他组都出现了瘤.
- 与模型组相比,甲胺治疗导致瘤较少和较小.
- 甲胺干预改善了结肠组织中ZO-1和奥克卢丁的表达,表明增强了肠道屏障功能.
结论:
- 甲福明在小鼠模型中显示出对结直肠癌 (CRC) 的保护作用.
- 甲胺通过恢复紧密结合蛋白来改善肠粘膜屏障功能.
- 这些发现表明,在特定剂量范围内,甲福明可能是预防CRC的可行选择.
相关概念视频
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...


